Weight, Hair and Skin Drugs
Max@maximilian
The idea
I think the obesity drug boom is just the start of a much bigger shift in medicine toward treatments for how people look and feel, so I built a basket around the whole wave: the obesity leaders and challengers, plus newer peptides and pills for hair loss, skin and hormones, the telehealth sellers that distribute them directly, and the suppliers that make the pens and gear everyone needs regardless of who wins.
What it owns
- Smaller biotechs and established drugmakers are racing to win market share in obesity with new pills and shots designed to rival the current leaders. · Amgen Inc.It is pursuing the obesity market with MariTide, a once-monthly shot designed to offer simpler dosing than weekly competitors while maintaining strong weight loss., Viking Therapeutics, Inc.It is a smaller challenger developing both a shot and an oral pill for obesity, with a final-stage trial underway to establish competitive efficacy and safety., Altimmune, Inc.It is developing a shot targeting both weight loss and fatty liver disease, offering a dual benefit that could differentiate it from single-indication competitors., Rhythm Pharmaceuticals, Inc.It sells a peptide drug for rare genetic forms of obesity, serving a niche patient population that larger competitors are not prioritizing., Pfizer Inc.It acquired obesity drug programs after its internal efforts stalled, representing a major, well-funded company placing a bet on the next wave of weight-loss treatments., Structure Therapeutics Inc.It is developing a daily oral obesity pill designed for lower manufacturing costs, representing a higher-risk bet on a pill format competing with current market leaders., AstraZeneca PLCIt is advancing its own oral GLP-1 pill and partnering on artificial intelligence for heart and metabolic disease, betting on the obesity and related-disease opportunity.25%
- These companies sell the blockbuster weight-loss peptides that created this market and continue to dominate obesity drug sales. · Eli Lilly and CompanyIt leads the weight-loss shot market with Zepbound and has an oral pill moving through European regulatory approval, establishing it as the dominant player in obesity sales., Novo Nordisk A/SIt makes Wegovy and is the other giant of the obesity drug boom, positioned as a recovery play if it stabilizes its market share and maintains sales growth.19%
- Peptide and protein drugs for skin disease, aesthetics and hormone conditions extend the same look-and-feel-better demand across multiple patient needs. · Protagonist Therapeutics, Inc.It is advancing an oral peptide pill for psoriasis, demonstrating that peptide technology can expand beyond shots and obesity to other therapeutic areas., Ascendis Pharma A/SIt develops long-acting hormone peptides that require less frequent dosing, addressing the convenience-driven demand central to this market., AbbVie Inc.It owns Botox and a large aesthetics business, making it the established player in the cash-pay market for appearance-enhancing treatments., Evolus, Inc.It sells a Botox alternative directly to aesthetics clinics that serve cash-paying patients, providing focused exposure to the appearance-enhancement market.16%
- These companies make the pens, vial parts, needles and production equipment that obesity and peptide drugs require, regardless of which drug wins. · West Pharmaceutical Services, Inc.It manufactures the components inside injector pens and vials used by weekly obesity and peptide shots, creating consistent demand as those drugs grow., Thermo Fisher Scientific Inc.It manufactures drugs under contract for other companies, earning revenue as peptide and obesity drug production volumes increase across the market., Danaher CorporationIt supplies the tools and equipment that drugmakers use to manufacture biologic drugs, gaining as companies invest in new production capacity to meet obesity drug demand., Becton, Dickinson and CompanyIt manufactures syringes and pen needles used in injected obesity and peptide drugs, providing ongoing revenue as long as injected treatments remain a significant market share.14%
- Hair loss is emerging as a major cash-pay market, with the first new pills in decades moving through approval and reaching patients. · Veradermics, Inc.It developed the first new hair-loss pill in years, won a late-stage trial and represents a concentrated bet on this emerging treatment category., Absci CorporationIt is developing an antibody treatment for hair loss, representing an earlier and higher-risk approach to the emerging hair-loss drug category.9%
- Online clinics sell weight-loss, hair-loss and sexual-health treatments directly to consumers paying out of pocket, capturing multiple layers of this take. · Hims & Hers Health, Inc.It sells weight-loss, hair-loss and sexual-health treatments online to cash-paying patients, providing direct exposure to multiple segments of this take through one platform., LifeMD, Inc.It operates a smaller online clinic selling weight-loss and cash-pay treatments to patients, complementing the larger telehealth players in this take.8%
- Cash10%